CVA Family Office’s BioMarin Pharmaceuticals BMRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $4.95K | Sell |
90
-14
| -13% | -$770 | ﹤0.01% | 891 |
|
|
2025
Q1 | $7.35K | Buy |
104
+65
| +167% | +$4.6K | ﹤0.01% | 843 |
|
|
2024
Q4 | $2.56K | Buy |
39
+33
| +550% | +$2.17K | ﹤0.01% | 953 |
|
|
2024
Q3 | $422 | Sell |
6
-56
| -90% | -$3.94K | ﹤0.01% | 1246 |
|
|
2024
Q2 | $5.1K | Buy |
62
+12
| +24% | +$988 | ﹤0.01% | 828 |
|
|
2024
Q1 | $4.37K | Hold |
50
| – | – | ﹤0.01% | 850 |
|
|
2023
Q4 | $4.82K | Buy |
+50
| New | +$4.82K | ﹤0.01% | 822 |
|
|
2023
Q3 | – | Sell |
-55
| Closed | -$4.77K | – | 319 |
|
|
2023
Q2 | $4.77K | Hold |
55
| – | – | ﹤0.01% | 818 |
|
|
2023
Q1 | $5.35K | Sell |
55
-5
| -8% | -$486 | ﹤0.01% | 768 |
|
|
2022
Q4 | $6.21K | Buy |
60
+5
| +9% | +$517 | ﹤0.01% | 716 |
|
|
2022
Q3 | $5K | Hold |
55
| – | – | ﹤0.01% | 711 |
|
|
2022
Q2 | $5K | Sell |
55
-5
| -8% | -$455 | ﹤0.01% | 737 |
|
|
2022
Q1 | $5K | Buy |
60
+10
| +20% | +$833 | ﹤0.01% | 763 |
|
|
2021
Q4 | $4K | Sell |
50
-75
| -60% | -$6K | ﹤0.01% | 766 |
|
|
2021
Q3 | $10K | Buy |
+125
| New | +$10K | 0.01% | 294 |
|
|
2021
Q1 | – | Sell |
-125
| Closed | -$11K | – | 776 |
|
|
2020
Q4 | $11K | Hold |
125
| – | – | 0.01% | 293 |
|
|
2020
Q3 | $10K | Hold |
125
| – | – | 0.01% | 294 |
|
|
2020
Q2 | $15K | Hold |
125
| – | – | 0.01% | 235 |
|
|
2020
Q1 | $11K | Buy |
+125
| New | +$11K | 0.01% | 233 |
|